Wayne A. Marasco, MD, PhD
Professor of Medicine, Harvard Medical School
Office phone: 617-632-2153
Website: Marasco Laboratory
Preferred contact method: email
Area of Research
Human Monoclonal Antibody-Based Immunotherapy
Dana-Farber Cancer Institute
450 Brookline Avenue
Jimmy Fund 824
Boston, MA 02215
Dr. Marasco received his PhD in 1980 from the University of Connecticut School of Medicine and postdoctoral training at the University of Michigan Medical School, where he also earned an MD in 1986 and completed training in internal medicine. He received his subspecialty training in infectious diseases at Harvard Medical School, and joined DFCI in 1989. In 2003, he founded the National Foundation of Cancer Research Center for Therapeutic Antibody Engineering to expand the use of human monoclonal antibodies in the treatment of cancer. In 2009, he was listed among 13 top scientists in their field as the 21st century medicine "Pioneeers of Medicine Progress" by US News & World report. He is head of an accomplished research laboratory in the area of cancer and infectious disease immunotherapy.
- "Pioneer of Medical Progress", U.S. News & World Report (among 13 top scientists in their field), 2009
ResearchHuman Monoclonal Antibody-Based Immunotherapy
Our laboratory focuses on the engineering and use of human antibodies in discovery research and disease treatment. We are working in three disease areas: cancer, emerging infectious diseases, and HIV/AIDS, a breadth of investigation made possible by the development and use of state-of-the-art tools in the field of antibody engineering that support our research efforts. More recently, we have been developing humanized mice to support our targeted immunotherapy studies and to investigate the roles of human adult stem cells in regenerative medicine.
We have active research programs in cancer immunotherapy that include the following targets: CXCR4 for breast cancer, G250 (CA IX) for renal cell carcinoma, CCR4 for cutaneous T cell lymphomas (CTCLs), and IGHV1-69 encoded B-cell receptors (BCR) for treatment of an aggressive form of chronic lymphocytic leukemia (CLL).
We are also developing immunotherapies that can modulate immune T cell activity to boost natural cancer immunity and response to cancer vaccines. Regulatory T cells (Tregs) exert control by dampening the immune response to prevent host tissue damage but these cells are also co-opted by cancer cells which leads to immune evasion. Tregs express high levels of CCR4 and we have demonstrated in vitro and in vivo that anti-CCR4 Mabs can reverse this immune suppression and reverse T cell "exhaustion" thereby restoring host immunity.
We use human monoclonal antibodies in functional and structural studies to understand mechanisms of viral entry, identify common targets that povide broad-spectrum protection, and develop strategies that prevent the viruses from undergoing neutralization escape. Vaccinated/infected humans and humanized mice are the B-cell sources of antibody genes for these studies. We are studying human pathogenic viruses that include influenza A, West Nile Virus, SARS- and MERS-CoVs and HIV/AIDS. As with our cancer studies, we are investigating whether human antibodies that are directed to surface proteins on T-cells or their secreted products can reverse T-cell "exhaustion" which is known to occur in HIV-1/AIDS with the goal of lowering viral loads, prolonging health and preventing the spread of HIV-1. We are using our humanized mice in the area of anti-microbial immunity to develop broad-spectrum anti-viral vaccines.
The laboratory has made major scientific advances in the treatment of infectious diseases and cancer (see www.marascolab.org).
- Zhu, Quan, PhD
- Tallarico, Aimee, PhD
- Sun, Jiusong, PhD
- Edward, Cohen, PhD
- Avnir, Yuval, PhD
- Biswas, Subhabrata (Brad), PhD
- Chang, DeKuan, PhD
- Fu, Ying, MD, PhD
- Tang, Xianchun, PhD
- Zhang, Zhen, PhD